US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab due to Omicron BA.2 Subvariant

London UK - 25 March 2022 -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials